Astrana Health Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Astrana Health wird ein Gewinn- und Umsatzwachstum von 20.3% bzw. 20.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 18.9% pro Jahr wachsen soll.

Wichtige Informationen

20.3%

Wachstumsrate der Gewinne

18.9%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	21.1%
Wachstumsrate der Einnahmen	20.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Nov 10

Recent updates

Astrana Health, Inc.'s (NASDAQ:ASTH) 33% Cheaper Price Remains In Tune With Earnings

Nov 18

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Nov 10

Astrana Health, Inc.'s (NASDAQ:ASTH) P/E Is Still On The Mark Following 25% Share Price Bounce

Oct 04

Is Astrana Health, Inc. (NASDAQ:ASTH) Trading At A 21% Discount?

Sep 26

Astrana Health's (NASDAQ:ASTH) Returns On Capital Not Reflecting Well On The Business

Sep 12

Is Astrana Health (NASDAQ:ASTH) Using Too Much Debt?

Aug 28

Astrana Health, Inc.'s (NASDAQ:ASTH) 29% Jump Shows Its Popularity With Investors

Aug 02

Is There Now An Opportunity In Astrana Health, Inc. (NASDAQ:ASTH)?

Jun 19

Capital Allocation Trends At Astrana Health (NASDAQ:ASTH) Aren't Ideal

Jun 02

Astrana Health, Inc. (NASDAQ:ASTH) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 09

Investors Still Waiting For A Pull Back In Astrana Health, Inc. (NASDAQ:ASTH)

Apr 15

At US$40.82, Is Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Worth Looking At Closely?

Feb 25

Is Apollo Medical Holdings (NASDAQ:AMEH) Using Too Much Debt?

Feb 07

Apollo Medical Holdings: Good Company, Not Quite A Hold

Jan 17

With Apollo Medical Holdings, Inc. (NASDAQ:AMEH) It Looks Like You'll Get What You Pay For

Dec 27

Does This Valuation Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Imply Investors Are Overpaying?

Apr 20

Is Apollo Medical Holdings (NASDAQ:AMEH) A Risky Investment?

Mar 21

Apollo Medical Holdings (NASDAQ:AMEH) Has More To Do To Multiply In Value Going Forward

Jan 06

Is Apollo Medical Holdings (NASDAQ:AMEH) Using Too Much Debt?

Dec 16

Apollo Medical to acquire Valley Oaks Medical Group

Oct 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ASTH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,310	95	N/A	128	6
12/31/2025	2,611	71	84	108	10
12/31/2024	1,981	57	56	98	9
9/30/2024	1,722	62	70	82	N/A
6/30/2024	1,592	68	50	64	N/A
3/31/2024	1,454	62	52	66	N/A
12/31/2023	1,387	61	40	68	N/A
9/30/2023	1,328	45	112	134	N/A
6/30/2023	1,297	46	61	83	N/A
3/31/2023	1,218	45	46	66	N/A
12/31/2022	1,144	45	59	82	N/A
9/30/2022	1,045	58	-40	-15	N/A
6/30/2022	955	69	41	72	N/A
3/31/2022	861	70	48	84	N/A
12/31/2021	774	69	51	70	N/A
9/30/2021	756	70	63	80	N/A
6/30/2021	709	53	57	65	N/A
3/31/2021	698	47	64	65	N/A
12/31/2020	687	38	45	46	N/A
9/30/2020	689	35	52	52	N/A
6/30/2020	665	22	47	48	N/A
3/31/2020	630	18	7	8	N/A
12/31/2019	561	14	13	14	N/A
9/30/2019	488	4	3	4	N/A
6/30/2019	499	10	-11	-10	N/A
3/31/2019	492	9	16	17	N/A
12/31/2018	520	11	24	25	N/A
9/30/2018	506	28	46	47	N/A
6/30/2018	436	24	N/A	41	N/A
3/31/2018	395	24	N/A	35	N/A
12/31/2017	356	26	N/A	52	N/A
9/30/2017	336	13	N/A	44	N/A
6/30/2017	323	11	N/A	45	N/A
3/31/2017	317	12	N/A	47	N/A
12/31/2016	306	11	N/A	22	N/A
12/31/2015	313	13	N/A	32	N/A
12/31/2014	134	-1	N/A	16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ASTHDas prognostizierte Gewinnwachstum (20.3% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: ASTHDie Erträge des Unternehmens (20.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.3% pro Jahr).

Hohe Wachstumserträge: ASTHEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: ASTHDie Einnahmen des Unternehmens (20.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: ASTHDie Einnahmen des Unternehmens (20.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ASTH in 3 Jahren voraussichtlich hoch sein wird

Astrana Health Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Price target increased by 7.8% to US$63.29

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 8.0% to US$60.00

Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024

Price target increased by 8.7% to US$58.71

Recent updates

Astrana Health, Inc.'s (NASDAQ:ASTH) 33% Cheaper Price Remains In Tune With Earnings

Investor sentiment deteriorates as stock falls 30%

Now 26% undervalued after recent price drop

Astrana Health, Inc. (NasdaqCM:ASTH) agreed to acquire Prospect Health Plan, Inc. from Prospect Medical Holdings, Inc.

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrana Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Now 20% undervalued

Astrana Health, Inc.'s (NASDAQ:ASTH) P/E Is Still On The Mark Following 25% Share Price Bounce

Price target increased by 7.8% to US$63.29

Is Astrana Health, Inc. (NASDAQ:ASTH) Trading At A 21% Discount?

Now 21% undervalued

Investor sentiment improves as stock rises 15%

Co-Founder & Vice Chairman exercised options to buy US$926k worth of stock.

Astrana Health's (NASDAQ:ASTH) Returns On Capital Not Reflecting Well On The Business

Is Astrana Health (NASDAQ:ASTH) Using Too Much Debt?

Independent Director exercised options and sold US$485k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 8.0% to US$60.00

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024

Price target increased by 8.7% to US$58.71

Astrana Health, Inc.'s (NASDAQ:ASTH) 29% Jump Shows Its Popularity With Investors

Astrana Health, Inc. (NasdaqCM:ASTH) entered into Securities Purchase Agreement to acquire Heritage Physician Networks from Heritage Health Systems Inc.

Astrana Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investor sentiment improves as stock rises 19%

Is There Now An Opportunity In Astrana Health, Inc. (NASDAQ:ASTH)?

Capital Allocation Trends At Astrana Health (NASDAQ:ASTH) Aren't Ideal

New minor risk - Shareholder dilution

Astrana Health, Inc. (NASDAQ:ASTH) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Astrana Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Astrana Health, Inc. to Report Q1, 2024 Results on May 07, 2024

Astrana Health, Inc., Annual General Meeting, Jun 12, 2024

Astrana Health, Inc. Announces Redesignation of Albert Young from Chief Administrative Officer to A New Role as Senior Vice President of Health Affairs

Investors Still Waiting For A Pull Back In Astrana Health, Inc. (NASDAQ:ASTH)

New minor risk - Shareholder dilution

Astrana Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

At US$40.82, Is Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Worth Looking At Closely?

Is Apollo Medical Holdings (NASDAQ:AMEH) Using Too Much Debt?

Apollo Medical Holdings, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Apollo Medical Holdings, Inc. Announces Management Changes

Apollo Medical Holdings: Good Company, Not Quite A Hold

With Apollo Medical Holdings, Inc. (NASDAQ:AMEH) It Looks Like You'll Get What You Pay For

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings: EPS exceeds analyst expectations

Apollo Medical Holdings, Inc. (NasdaqCM:AMEH) announces an Equity Buyback for $100 million worth of its shares.

Apollo Medical Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Returns On Capital At Apollo Medical Holdings (NASDAQ:AMEH) Have Stalled

Should You Investigate Apollo Medical Holdings, Inc. (NASDAQ:AMEH) At US$30.62?

Apollo Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Apollo Medical Holdings (NASDAQ:AMEH) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Apollo Medical Holdings, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Returns At Apollo Medical Holdings (NASDAQ:AMEH) Appear To Be Weighed Down

Apollo Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023

A Look At The Intrinsic Value Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH)

Apollo Medical Holdings, Inc. (NasdaqCM:AMEH) entered into a definitive agreement to acquire Assets of Texas Independent Providers, LLC.

We Think Apollo Medical Holdings (NASDAQ:AMEH) Can Stay On Top Of Its Debt

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Medical Holdings, Inc. Provides Earnings Guidance for the Year 2023

Apollo Medical Holdings' (NASDAQ:AMEH) Returns On Capital Are Heading Higher

Does This Valuation Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Imply Investors Are Overpaying?

Is Apollo Medical Holdings (NASDAQ:AMEH) A Risky Investment?

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS and revenues exceed analyst expectations